<DOC>
	<DOCNO>NCT00642577</DOCNO>
	<brief_summary>This 2 arm study ass efficacy safety Avastin combination irinotecan + 5-fluorouracil/folinic acid , versus irinotecan + fluorouracil/folinic acid alone , first line treatment Chinese patient metastatic colorectal cancer . Patients randomize 2:1 receive 6-weekly cycle Avastin ( 5mg/kg iv every 2 week ) + irinotecan 125mg/m2 iv / leucovorin 20mg/m2 iv / fluorouracil 500mg/m2 iv weekly 4 week , 6-weekly cycle irinotecan 125mg/m2 iv / leucovorin 20mg/m2 iv / fluorouracil 500mg/m2 iv weekly 4 week . The anticipated time study treatment disease progression , sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Chemotherapy Chinese Patients With Metastatic Colorectal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; histologically confirm adenocarcinoma colon rectum , metastatic disease ; &gt; =1 measurable lesion ; ECOG performance status &lt; =1 . prior systemic therapy advance metastatic disease ; adjuvant neoadjuvant treatment nonmetastatic disease past 6 month ; malignancy within past 5 year , except cure basal cell cancer skin cure cancer situ cervix ; clinically significant cardiovascular disease past 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>